drugset / Trial / NCT04540406
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Phase 2
Completed
42 enrolled
Notitia Biotechnologies Company
Rutgers University · collabUniversity of South Florida · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or confirmed symptomatic COVID-19 patients.
Timeline
- Start
- 2021-11-02
- Primary completion
- 2022-03-14
- Completion
- 2022-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NBT-NM108 | Other / unclassified | 30 g | Oral |
Indications
No indication recorded.